Program
sotevtamab
Also written as “Sotevtamab” and “AB-16B5”.
Its studies are mostly in Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Neoplasm Metastasis, led by 2 companies.
Drug pageSotevtamab: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alethia Biotherapeutics | 31 open or running | phase 2since Apr 23, 2020 | Mar 30, 2015 | none ahead |
| ImmunityBioits history only | 10 open or running | phase 1since Nov 20, 2025 | Nov 20, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Alethia Biotherapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Mar 30, 2015First study: phase 1 study in Neoplasm MetastasisFirst studyNCT02412462 · 15 enrolled · Canada
- Apr 23, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04364620 · 35 enrolled · United States, Canada
- Jul 28, 2021Named sotevtamabINNProposed as its International Nonproprietary Name in WHO's List 125
- Nov 17, 2023Phase 2 study in Colorectal NeoplasmsNCT06225843 · 17 planned · Canada
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 Alethia Biotherapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06225843Colorectal Neoplasms · Canada | 2 | Recruiting | Mar 2026 | 17 |
| NCT04364620Carcinoma, Non-Small-Cell Lung · United States, Canada | 2 | Completed | Dec 31, 2023 | 35 |
| NCT02412462Neoplasm Metastasis · Canada | 1 | Completed | Jan 2017 | 15 |
How it is read
Names in the registry
- “Sotevtamab”, 2 entries
- “AB-16B5”, 2 entries
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Colorectal Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.